Patents by Inventor Scott McCauley

Scott McCauley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11814679
    Abstract: The present disclosure provides methods and compositions relating to isolated CD8+ T cells expressing a disease antigen-specific T cell receptor, as well as nucleic acids encoding the V? and V? polypeptide pairs of T cell receptors (TCRs) of such disease antigen-specific T cells. Such disease antigen-specific CD8+ T cells are obtainable from the periphery (e.g., blood) of a subject having a disease amenable to treatment with an IL-10 agent. The present disclosure also contemplates therapeutic methods and compositions relating to administration of isolated disease antigen-specific CD8+ T cells to a subject, as well as therapeutic methods and compositions relating to CD8+ T cells genetically modified to express a disease antigen-specific TCR and/or chimeric antigen receptor.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: November 14, 2023
    Assignee: Eli Lilly and Company
    Inventors: John Brian Mumm, Ivan Ho Chan, Scott McCauley, Scott Ogg, Martin Oft
  • Patent number: 11634505
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: April 25, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Victoria Smith, Scott McCauley
  • Publication number: 20220413225
    Abstract: A diagnostic voltage or current path can be used for each MEMS actuator control channel to detect and diagnose faults in the actuator control signal path. Multiple measurement points provide additional capabilities of isolating faults among multiple subassemblies or components in the control signal path. The diagnostic voltage or current path uses ADC(s) and multiplexers to monitor multiple control channels and/or multiple measurement points in each control channel. Digitized voltages, or currents in the case of magnetic actuators, read from the diagnostic ADC are compared to expected values to detect and isolate faults.
    Type: Application
    Filed: January 12, 2022
    Publication date: December 29, 2022
    Inventors: Dennis Yen, Scott McCauley, Kevin Yasumura
  • Patent number: 11529831
    Abstract: A central tire inflation system configured to monitor and maintain an air pressure on the tires of a vehicle includes a housing, a central processing unit, a controller, and a valve. The housing has a plurality of walls and a bottom forming an interior volume. The central processing unit has the necessary electronics to receive, store, transmit and manipulate data. The controller has a plurality of modes of operation wherein the modes of operation include default parameters for air pressure within the tires of the vehicle. The valve is configured to direct air flow as required into or out of the tires, the valve being operably coupled to the controller. The central tire inflation system is configured to monitor air pressure of the tires and provide inflation or deflation thereof based the mode of operation.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: December 20, 2022
    Assignee: Airdown, Inc.
    Inventors: Scott McCauley, Alfred Robert Tomlinson
  • Publication number: 20210054101
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Application
    Filed: September 10, 2020
    Publication date: February 25, 2021
    Inventors: Victoria SMITH, Scott MCCAULEY
  • Publication number: 20200101803
    Abstract: A central tire inflation system configured to monitor and maintain an air pressure on the tires of a vehicle includes a housing, a central processing unit, a controller, and a valve. The housing has a plurality of walls and a bottom forming an interior volume. The central processing unit has the necessary electronics to receive, store, transmit and manipulate data. The controller has a plurality of modes of operation wherein the modes of operation include default parameters for air pressure within the tires of the vehicle. The valve is configured to direct air flow as required into or out of the tires, the valve being operably coupled to the controller. The central tire inflation system is configured to monitor air pressure of the tires and provide inflation or deflation thereof based the mode of operation.
    Type: Application
    Filed: December 2, 2019
    Publication date: April 2, 2020
    Applicant: Airdown, Inc.
    Inventors: Scott McCauley, Alfred Robert Tomlinson
  • Patent number: 10493808
    Abstract: A central tire inflation system that is operably coupled to a vehicle wherein the system is operable to monitor and control the tire air pressure of the vehicle. The central tire inflation system includes a wheel assembly that includes a housing having an annular central portion with opposing arm members extending outward therefrom. The annular central portion includes an interior volume having a valve and a bearing/cap assembly. A controller is further provided wherein the controller includes a central processing unit. A valve is disposed within the controller and is operably coupled to three ports wherein a first port provides a fluid connection to the wheel assembly. The central tire inflation system further includes a control panel having a graphical display operable to provide a user interface for operation of the central tire inflation system. A plurality of operational modes are provide for selection by a user.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: December 3, 2019
    Inventors: Scott McCauley, Alfred Robert Tomlinson
  • Patent number: 10350270
    Abstract: Interleukin-15 muteins and other interleukin-15-related molecules are described, as well as methods of identifying interleukin-15 muteins and other interleukin-15-related molecules. Also described herein are modifications of the foregoing, which modifications may enhance a property (e.g., half-life) of the muteins or other molecules compared to human interleukin-15. Pharmaceutical compositions and methods of use are also described herein.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: July 16, 2019
    Assignee: Armo Biosciences, Inc.
    Inventor: Scott McCauley
  • Publication number: 20190127486
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an l=g light chain (or functional fragment thereof).
    Type: Application
    Filed: January 10, 2019
    Publication date: May 2, 2019
    Inventors: Victoria SMITH, Scott MCCAULEY
  • Publication number: 20190032134
    Abstract: The present disclosure provides methods and compositions relating to isolated CD8+ T cells expressing a disease antigen-specific T cell receptor, as well as nucleic acids encoding the V? and V? polypeptide pairs of T cell receptors (TCRs) of such disease antigen-specific T cells. Such disease antigen-specific CD8+ T cells are obtainable from the periphery (e.g., blood) of a subject having a disease amenable to treatment with an IL-10 agent. The present disclosure also contemplates therapeutic methods and compositions relating to administration of isolated disease antigen-specific CD8+ T cells to a subject, as well as therapeutic methods and compositions relating to CD8+ T cells genetically modified to express a disease antigen-specific TCR and/or chimeric antigen receptor.
    Type: Application
    Filed: January 10, 2017
    Publication date: January 31, 2019
    Inventors: John Brian Mumm, Ivan Ho Chan, Scott McCauley, Scott Ogg, Martin Oft
  • Publication number: 20180086845
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Application
    Filed: September 5, 2017
    Publication date: March 29, 2018
    Inventors: Scott McCauley, Maria Vaysberg
  • Publication number: 20170246253
    Abstract: Interleukin-15 muteins and other interleukin-15-related molecules are described, as well as methods of identifying interleukin-15 muteins and other interleukin-15-related molecules. Also described herein are modifications of the foregoing, which modifications may enhance a property (e.g., half-life) of the muteins or other molecules compared to human interleukin-15. Pharmaceutical compositions and methods of use are also described herein.
    Type: Application
    Filed: October 12, 2015
    Publication date: August 31, 2017
    Inventor: Scott McCauley
  • Publication number: 20170183421
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Application
    Filed: December 12, 2016
    Publication date: June 29, 2017
    Inventors: Victoria Smith, Scott McCauley
  • Patent number: 9550836
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: January 24, 2017
    Assignee: Gilead Biologics, Inc.
    Inventors: Victoria Smith, Scott McCauley
  • Publication number: 20160159923
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Application
    Filed: August 28, 2015
    Publication date: June 9, 2016
    Inventors: Scott McCauley, Maria Vaysberg
  • Publication number: 20160068583
    Abstract: Interleukin-10 muteins and other interleukin-10-related molecules are described, as well as methods of identifying interleukin-10 muteins and other interleukin-10-related molecules. Also described herein are modifications of the foregoing, which modifications may enhance a property (e.g., half-life) of the muteins or other molecules compared to human interleukin-10. Particular interleukin-10 muteins and related molecules have comparable immunogenicity to human interleukin-10 and/or bioactivity at least comparable to human interleukin-10. Pharmaceutical compositions and methods of use are also described herein.
    Type: Application
    Filed: April 23, 2014
    Publication date: March 10, 2016
    Inventors: Peter Van Vlasselaer, Scott McCauley
  • Patent number: 9260532
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: February 16, 2016
    Assignee: Gilead Biologics, Inc.
    Inventors: Scott McCauley, Maria Vaysberg
  • Patent number: 9120863
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: September 1, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott McCauley, Maria Vaysberg
  • Patent number: 9078375
    Abstract: A hardware plane providing improved cooling air flow is disclosed herein. The hardware plane includes one or more minor planes extending from a major plane so that a gap or opening is formed for air flow. A cooling unit moves air through the gap and across the surface of hardware cards connected to the hardware plane in order to cool the hardware plane and the hardware cards. The hardware plane allows for both improved cooling air flow and for space-efficient and cost-efficient positioning of hardware cards, data buses, and control buses.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: July 7, 2015
    Assignee: Google Inc.
    Inventors: Roy Michael Bannon, Scott McCauley
  • Publication number: 20150140580
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Application
    Filed: February 29, 2012
    Publication date: May 21, 2015
    Applicant: Gilead Biologics, Inc.
    Inventors: Victoria Smith, Scott McCauley